Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare yet debilitating neuropathy characterized by chronic inflammation, demyelination, and axonal degeneration. Current treatments, including corticosteroids, intravenous immunoglobulins, subcutaneous immunoglobulins, and plasma exchange, often result in inadequate responses and relapse. Efgartigimod, a novel Fc receptor (FcRn) blocker, has emerged as a promising therapy by reducing pathogenic autoantibodies. Recent clinical trials, particularly the ADHERE and ADVANCE-CIDP studies, demonstrate its efficacy in prolonging clinical response and reducing relapse rates. This review explores CIDP’s pathogenesis, current treatments, and the potential of efgartigimod to revolutionize the management of this challenging condition.
Sohail et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: